Custom Search

Thursday, July 21, 2011

New class of antidiabetic drugs which lower blood glucose by urinary excretion of glucose.

Anti diabetic drug which could lower blood glucose level by passing out blood glucose in urine.
Diabetes is a condition where sugar level in blood is not controlled by our body because of which a constant high blood sugar level becomes prime health damaging factor for person affected with diabetes.

What if blood glucose is eliminated out of our body through urine ?

Increased blood glucose level in diabetes make patient susceptible to further complications like nerve damage and kidney failure, heart disease and stroke.

Pharmaceutical companies have developed such drugs and unfortunately one of such drug got disapproved , was about to hit US market soon, it got disapproved by US FDA as there were few cases wherein patients participated in the clinical trials were found to be affected with cancer.

It could have been possible to treat both types of diabetes type 1 diabetes and type 2 diabetes patients as well as patients which do not respond to insulin with such antidiabetic drug.

The drug name is Dapagliflozin a SGLT2 inhibitor drug which is an experimental (new drug application) (NDA), diabetes once a day pill being developed jointly by pharmaceutical companies Bristol-Myers Squibb and AstraZeneca.

9 Cases of bladder cancer were observed out of 5,478 patients treated with this drug. Compared to a only one case of bladder cancer in control study group of 3,156 patients.
Six patients out of these 10 patients were found to develop hematuria (blood in the urine).

9 women out of 2,223 women treated with the drug were found to be affected with breast cancer.

As the drug leads to elimination of glucose though urine , high concentration of glucose is responsible for urinary tract infection as well.

Each and every drug which apply for permission for marketing in United States is required to exhibit through prompt clinical trials on human volunteers that it does not pose any safety risks to patients, there are no side effects or if at all are not so serious, further more it is also required that the efficacy of the new drug is also superior to the present marketed drugs which are used for same indication(s).

Mode of action of SGLT2 inhibitor anti diabetic drugs:


SGLT2 inhibitor drug act by inhibiting enzymes and proteins system sodium-glucose co-transporter 2 (SGLT2) which is responsible for reabsorption of glucose from kidney’s proximal tubules, inhibiting the protein and enzyme system SGLT2 leads to increased excretion of glucose molecule through urine.

The drug may not be effective in diabetes patients suffering from kidney failure; they would require conventional antidiabetic drugs.

Nanoparticles of insulin in place of painful injections in treatment for diabetes patients, transdermal , nasal drug delivery systems



1 comment:

Anonymous said...

Good invention but the drug must be safe then it will be useful .
US FDA is very perticular about the safty americans should thank them

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2015 all rights reserve www.pharmacistspharmajournal.org